CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) Latest Company News

Sep 17, 2026, 12:00 UTC
Charles River Laboratories International, Inc. introduced rapid cell banking programs combining rapid cell bank and release packages with Next-Generation Sequencing characterization to accelerate release timelines for biopharmaceutical and advanced therapy developers.
Source:
- businesswire.com
Sep 14, 2026, 14:19 UTC
Charles River Laboratories' stock price extended its decline to 4%.
Source:
- finance.sina.cn
Sep 14, 2026, 14:13 UTC
Charles River Laboratories' stock fell rapidly by 1.1%.
Source:
- finance.sina.cn
Aug 11, 2026, 09:30 UTC
Charles River Laboratories International's stock reached a new 52-week high on Tuesday, trading as high as $277.07.
Source:
- defenseworld.net
Aug 5, 2026, 00:00 UTC
Charles River Laboratories International, Inc. repurchased $100 million of its common stock during the second quarter of 2026 at an average price of $174 per share.
Aug 5, 2026, 00:00 UTC
Charles River Laboratories International, Inc. reported its second quarter 2026 financial results, with total revenue of $1.00 billion, a GAAP net loss of $1.5 million, and non-GAAP diluted EPS of $3.02.
Source:
Jul 29, 2026, 00:00 UTC
Fortrea Holdings Inc. appointed David Smith as Interim Chief Financial Officer and principal financial officer, effective July 27, 2026.
Jul 13, 2026, 12:00 UTC
Charles River Laboratories announced a collaboration with Arovella Therapeutics to provide GMP NGS services for cell characterization, supporting Arovella's iNKT cell therapy platform for cancer treatment.
Source:
- wallstreet-online.de
- gurufocus.com
Jun 25, 2026, 05:00 UTC
Eli Lilly started a collaboration with about 100 smaller biotechs, including Charles River Laboratories, to work with AI models in return for their data.
Source:
- irishtimes.com

CRL

Charles River Laboratories International, Inc. introduced rapid cell banking programs combining rapid cell bank and release packages with Next-Generation Sequencing characterization to accelerate release timelines for biopharmaceutical and advanced therapy developers.

Charles River Laboratories' stock price extended its decline to 4%.

Charles River Laboratories' stock fell rapidly by 1.1%.

Charles River Laboratories International's stock reached a new 52-week high on Tuesday, trading as high as $277.07.

Charles River Laboratories International, Inc. repurchased $100 million of its common stock during the second quarter of 2026 at an average price of $174 per share.

Charles River Laboratories International, Inc. reported its second quarter 2026 financial results, with total revenue of $1.00 billion, a GAAP net loss of $1.5 million, and non-GAAP diluted EPS of $3.02.

Fortrea Holdings Inc. appointed David Smith as Interim Chief Financial Officer and principal financial officer, effective July 27, 2026.

Charles River Laboratories announced a collaboration with Arovella Therapeutics to provide GMP NGS services for cell characterization, supporting Arovella's iNKT cell therapy platform for cancer treatment.

Eli Lilly started a collaboration with about 100 smaller biotechs, including Charles River Laboratories, to work with AI models in return for their data.